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Abstract
Background. Recent research implicates antibiotic use as a potential contributor to child
obesity risk. In this narrative review, we examine current observational evidence on the rela-
tion between antibiotic use in early childhood and subsequent measures of child body mass.
Methods. We searched PubMed, Web of Science and the Cochrane Library to identify studies
that assessed antibiotic exposure before 3 years of age and subsequent measures of body mass
or risk of overweight or obesity in childhood.
Results. We identified 13 studies published before October 2017, based on a total of 6 81 332
individuals, which examined the relation between early life antibiotic exposure and measures
of child body mass. Most studies did not appropriately account for confounding by indication
for antibiotic use. Overall, we found no consistent and conclusive evidence of associations
between early life antibiotic use and later child body mass [minimum overall adjusted odds
ratio (aOR) reported: 1.01, 95% confidence interval (95% CI) 0.98–1.04, N = 2 60 556; max-
imum overall aOR reported: 2.56, 95% CI 1.36–4.79, N = 616], with no clinically meaningful
increases in weight reported (maximum increase: 1.50 kg at 15 years of age). Notable meth-
odological differences between studies, including variable measures of association and inclu-
sion of confounders, limited more comprehensive interpretations.
Conclusions. Evidence to date is insufficient to indicate that antibiotic use is an important
risk factor for child obesity, or leads to clinically important differences in weight. Further
comparable studies using routine clinical data may help clarify this association.
Introduction
Child obesity is a public-health issue of increasing global concern. In 2013, the age-standar-
dised prevalence of overweight and obesity among children and adolescents aged <20 years
was estimated to be 23.8% and 22.6% in high-income countries, and 12.9% and 13.4% in
low- and middle-income countries, among boys and girls, respectively [1–3]. The same
year, over 42 million (7%) children under 5 years of age were estimated to be overweight or
obese, with prevalence expected to increase to 11% by 2025 if current trends remain constant
[1–3]. Obesity during childhood is a risk factor for short- and long-term adverse outcomes,
including type-2 diabetes, hypertension and dyslipidaemia [4]. Given the anticipated burden
on individuals, health systems and economies, effective evidence-based strategies to prevent
and manage child obesity are essential.
Obesity risk is understood to result from a complex interplay of environmental and genetic
factors, including well-studied contributions from diet, physical activity and maternal factors
such as smoking and breastfeeding [5–7]. Additionally, increasing evidence has implicated
alterations in the intestinal microbiome in obesity development [8, 9]. In particular, antibiotic
use in early life has been hypothesised to promote obesity through metabolic dysregulation
caused by changes in the intestinal microbial composition [10, 11]. This dysregulation is
thought to encompass multiple potential pathways, including increases in microbiota-derived
energy, decreased energy requirements due to lowered intestinal defence, changes in hepatic
function and altered metabolic signalling [11].
Global antibiotic consumption was 34.8 billion daily defined doses (DDDs) in 2015, a 65%
increase compared with 2000 levels [12, 13]. Evidence among children suggests notable but var-
ied prevalence across populations and population subgroups [14–20]. For example, antibiotic use
among children up to 2 years of age was estimated to be 1365 prescriptions per 1000 persons in
the USA in 2010 [16], and 462 prescriptions per 1000 persons in Sweden in 2012 [19]. In both
cases, these were among the highest ratios across all age groups [16, 19]. This widespread use of
antibiotics among children, and their hypothesised metabolic effects [11], suggests the need to
more clearly determine the potential link between antibiotic use and obesity in this age group.
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A number of studies have assessed associations between anti-
biotic exposure and measures of body mass in children, with
inconsistent results regarding the existence and strength of asso-
ciations [21–33]. A more detailed understanding of these studies
is required to better identify and define future research aims and
inform public-health intervention. In this narrative review, we aim
to synthesise and summarise the current evidence on the relation
between early life antibiotic use and measures of child body mass.
Methods
We searched PubMed, Web of Science and the Cochrane Library
in order to identify studies published before October 2017 asses-
sing the relation between early childhood antibiotic use and mea-
sures of child body mass. Key words for antibiotics and body
mass-related outcomes were searched and combined using
Boolean operators as appropriate (online Supplementary
Methods).
Definitions of exposure and outcome
Early childhood antibiotic use was defined as exposure to any
pharmaceutical agent with antibacterial action between birth
and 3 years of age. This time period was selected as the micro-
biome is thought to be dynamic and in development until it
matures at this age [34], with antibiotic administration during
this period hypothesised to have a pronounced impact on the
development of the microbiome composition and related meta-
bolic functioning. No restrictions were placed on the nature or
frequency of the antibiotic exposure, or on the method of ascer-
tainment of antibiotic exposure.
Given the wide variation in definition of overweight and obes-
ity among children in research and clinical practice [1, 35–37],
measures of body mass included any outcome based on absolute
or relative weight or body mass index (BMI) between 2 and 18
years of age. This included BMI-for-age, weight-for-height or
binary measures such as overweight or obesity based upon any
of these indices. Studies examining self-reported or parental-
reported outcomes were included. The upper age limit of the
outcome was chosen given the interest in examining long-term
implications of early life antibiotic use across childhood.
Inclusion and exclusion criteria
We placed no restrictions on study design, publication date or sta-
tus in our selection criteria. Only English language publications
were reviewed. Studies based on children who were extremely
malnourished or with an underlying disease, or in children
born low birth weight or small for gestational age, were excluded,
given potential differences in their microbiome profile relative to
generally healthy, normal weight children [38, 39].
Literature search and synthesis
An initial search was performed by one author (EP) to identify
studies published before March 2016. This was repeated in
October 2017 by a second author (UP) to confirm the initial
search results and identify more recently published studies
(Fig. 1). Titles and abstracts of retrieved records were first
screened for inclusion in a full text review. The full texts of poten-
tially relevant studies were then examined to confirm inclusion
based on eligibility criteria. Additionally, the references of
included studies were also examined to assess the sensitivity of
the search strategy and identify any studies that may have been
missed. No further studies were identified using this method.
Studies published before March 2016 that were chosen for inclu-
sion during the second literature search (conducted by UP) were
consistent with those identified during the first literature search
(conducted by EP). Results of this second search are presented
in the online Supplementary Methods, and in Fig. 1.
Data on study design, sampling framework, inclusion and
exclusion criteria, sample characteristics, exposure and outcome
definition and ascertainment, covariates, statistical methodology
and main results were extracted from included studies. Results
of studies were grouped and summarised in terms of overall asso-
ciations between antibiotic exposure and measures of child body
mass, and associations by sex, window of antibiotic exposure,
repeated antibiotic exposure, antibiotic class and maternal BMI.
Qualitative review and evidence synthesis included an examin-
ation of the presence of associations, and their magnitude and
statistical strength. The consistency in trends of associations
across strata was also considered when examining windows of
exposure and repeated exposure to antibiotics. We assessed
whether studies adjusted for a number of confounders that may
plausibly influence associations between antibiotic use and obesity
among children (Box 1; online Supplementary Table S1). Other
extracted data on key study characteristics were also assessed in
order to understand individual studies’ strengths and limitations.
Given the wide variation in study characteristics, we did not per-
form a meta-analysis of study results.
Results
Study characteristics
We identified 13 observational studies, based on a total of 6 81
332 individuals, which permitted assessment of antibiotic expos-
ure before 3 years of age and subsequent measures of body mass
or risk of overweight or obesity in childhood (Fig. 1, Table 1)
[21–33]. None of the examined studies included assessment of
participants’ intestinal microbiota. Study designs included both
prospective [22, 26–28, 31, 33] and retrospective [21, 25, 29,
30, 32] cohort studies, and cross-sectional [24] and case–control
studies [23]. Apart from one study based in India [27] and two
multi-site studies [24, 28], all research was based on North
American [23, 25, 29, 30, 32] and European [21, 22, 26, 31, 33]
populations (Table 1; online Supplementary Tables S2 and S3).
Studies varied considerably with respect to a range of meth-
odological aspects, including exposure and outcome definition
and ascertainment, analytical strategy and inclusion of covariates
(Table 1, online Supplementary Tables S2 and S3). While all stud-
ies examined any antibiotic exposure in early life, one study was
able to capture only antibiotics prescribed for ear and lung infec-
tions [22]. Overall exposure windows of studies ranged from up to
6 months of age [22, 27–29] to up to ⩾3 years of age [25, 31].
Methods of antibiotic exposure ascertainment included parental
recall [22, 24, 26–28], prescription data [21, 23, 25, 28–31, 33]
and pharmacy data [32]. Outcomes reported ranged from con-
tinuous measures including BMI [24, 25] or BMI-for-age
z-score [26, 31, 33], weight-for-length z-score [27] or weight-
for-age z-score [28] and rate of weight gain [29] to binary
measures of overweight [22, 23, 26, 31, 33] or obesity [21, 30,
32]. Outcomes of relative body mass, including BMI-for-age,
weight-for-length, weight-for-age and binary classifications of
2 Uttara Partap et al.
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overweight and obesity based on these measures, were expressed
using a number of different references (Table 1). Outcome mea-
sures were by parental report in three studies [22, 24, 31], and
measured in clinical or research settings in the rest [21, 23, 25–
30, 32, 33]. Studies employed a variety of analytical methods to
assess associations, including those based upon covariance ana-
lysis [33], linear regression [24–27, 29], logistic regression [21–
23, 26, 32, 33], Cox proportional hazards models [30], generalised
estimating equations [28, 31] and longitudinal rate regression [29]
(Table 1, online Supplementary Tables S2 and S3). None of the
studies adjusted for all variables identified as potentially import-
ant confounders (Box 1, online Supplementary Table S3, Table 1).
Overall associations
Of the 13 studies identified, six reported overall measures of asso-
ciation. Of these, only one reported notable associations, between
antibiotic use before 12 months of age and overweight risk at 9
and 12 years of age [adjusted odds ratio (aOR) for overweight
at 12 years: 2.56, 95% confidence interval (95% CI) 1.36–4.79]
[23]. Five studies, of which two were based on populations of
over 38 000 individuals, reported no overall association between
antibiotic use and child body mass (Table 2) [22, 27–29, 32].
While all studies involved unmatched cohorts, the two larger
studies additionally included matched longitudinal sub-studies
of twins discordant for antibiotic exposure, with both confirming
the null associations observed in their main analyses [29, 32].
Modification of associations by sex
Sex-specific differences in susceptibility to infections and in drug
pharmacokinetics have been previously observed in humans
[40–42]. Potential differential effects of antibiotic use on child
overweight and obesity risk would thus be important to clarify.
Fig. 1. Schematic of literature search and exclusion for final review.
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Three of four studies stratifying analyses by sex reported associa-
tions persisting only in boys following adjustment for covariates
such as maternal BMI, smoking or socioeconomic status [23,
24, 33] (Table 3).
Window of antibiotic exposure
Data from animal models suggest that earlier antibiotic exposure
may have the capacity to more notably alter the intestinal micro-
biome, inducing metabolic changes leading to increased adiposity
[43]. Similar effects would be important to clarify in humans.
Evidence supporting specific early life windows of antibiotic
exposure among studies included in this review was limited.
Studies defined windows of exposure differently, often up to 6,
12 or 24 months of age [21–33]. Eight out of 13 studies stratified
by exposure window; of these, five reported some evidence of
stronger associations with antibiotic exposure in the first 3 to 6
months compared with later periods [21, 23, 26, 32, 33] (Fig. 2,
online Supplementary Table S4). However, this pattern was not
always consistently observed across multiple outcome measures
or time points within the same study [23, 26], and few studies
reported notable or consistent trends in associations across con-
secutive exposure windows [21, 23, 33]. No notable trends in asso-
ciation, or associations with exposure at <6 months of age was
noted in two studies [30, 31], whereas another study reported
associations between antibiotic use up to 24 months of age, but
not up to 6 months of age, and rate of weight gain [29] (online
Supplementary Table S4). Statistical tests comparing differences
between exposure window categories, or comparing trends across
categories, were not performed in any study [21, 23, 26, 29–33].
Repeated antibiotic exposure
Increased exposure to antibiotics in early life through repeated
courses may be expected to result in more pronounced alterations
in the intestinal microbiome, with potentially greater metabolic
effects. The existence of a dose-dependent relationship between
antibiotic use and childhood obesity risk would therefore be
important to examine. Seven studies assessed the relation between
the number of antibiotic courses and measures of child body mass
[21, 23, 27, 29–31, 33] (Fig. 3; online Supplementary Table S5). In
four studies, there was some evidence of association between
exposure to two or more antibiotic courses and increased
measures of body mass, or increasing magnitude of associations
with increasing course number [21, 29, 30, 33]. However, trends
were not consistent when examined across subgroups within
these studies [21, 29, 30, 33]. In two studies, no associations
were observed across any category of number of antibiotic courses
and measures of body mass [27, 31], while one study reported
decreased odds of overweight with exposure to an increasing
number of antibiotic courses [23]. Statistical tests for differences
or trends across categories of exposure were reported only in
this study, and were not notable ( p for linear trend >0.1 in all
cases; Figure 2, online Supplementary Table S5) [23].
Antibiotic class
Broad spectrum antibiotics are thought to affect a wider range of
intestinal microbiota, and thereby more notably alter intestinal
microbial composition, with potential subsequent implications
for metabolic dysregulation [44]. Evidence on effect modification
of obesity risk by antibiotic class in the studies identified here was
equivocal (Table 4). Of seven studies stratifying by antibiotic class,
three reported stronger associations between broad v. narrow
spectrum antibiotic use and later child body mass [28, 30, 33],
whilst three suggested no differences in strength of associations
[29, 31, 32]. One study stratified by anti-anaerobic activity,
suggesting increased obesity risk with greater than five courses
of antibiotics with anti-anaerobic activity (aOR 1.46, 95% CI
1.09–1.96) [21].
The effect of maternal BMI
Intestinal microbial composition in pregnant women has been
shown to differ by weight status, and to influence the offspring
intestinal microbiome [45]. Such resulting variations are hypothe-
sised to lead to differential weight-related responses to antibiotic
exposure among children of overweight v. normal weight mothers
[45]. Two studies examined maternal weight as a potential effect
modifier [22, 26]. One study reported associations between anti-
biotic use before 6 months of age and overweight at 7 years of age
only among children of normal weight mothers (aOR 1.54, 95%
CI 1.09–2.17) [22]. The other study observed similar associations
with child overweight at 38 months of age; however, these did not
persist to overweight at 7 years [26].
Addressing confounding by clinical indication
Confounding by clinical indication occurs when the association
between a clinical treatment and outcome is explained by the dis-
ease for which treatment was indicated [46]. Measures to identify
and address confounding by indication are thus crucial in studies
examining clinical treatments [46]. Four studies here considered
infection status, with three stratifying by, or adjusting for, infec-
tion type or severity [27, 28, 30]. Only one study clearly examined
the influence of the indication for antibiotic use on child obesity
risk, reporting associations between the presence of early life
infection and obesity (aOR 1.25, 95% CI 1.20–1.29), but not
between antibiotic use and obesity among children with infection
(aOR 1.01, 95% CI 0.98–1.04) [32]. Notably, including both
healthy children and those with untreated infection in the refer-
ence group resulted in associations between antibiotic use and
child obesity that were comparable with those observed in other
studies (aOR 1.20, 95% CI 1.17–1.22) [32], suggesting that
inappropriate accounting for confounding by indication may be
Box 1. Potential confounders of the association between early life
antibiotic use and child obesity
Early childhood infections
Delivery mode
Exclusive breastfeeding
Preterm birth and birth weight
Maternal smoking
Socio-economic status
Maternal BMI
Current wheeze/asthma
Lifestyle (diet and physical activity)
Siblingship
See Supplementary Table S1 for hypothesised pathways.
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Table 1. Summary of studies included in final review
Study N
Exposure definition
and age window
Outcome and age of
measurement
Anthropometric reference
used for outcome definition Covariates adjusted for
Saari et al. [33] 12 062 Any antibiotic at
<24 months
Adjusted difference (β) in zBMI at
⩾24 months
Finnish growth reference Maternal smoking after first trimester, parental relationship, mode of
delivery, birth weight and length (length for boys only)
aOR for overweight at ⩾24
months
Murphy et al. [24] 74 946 Any antibiotic at
<12 months
Adjusted difference (β) in BMI at
5–8 years
Age, sex, BMI measurement type (parental report or objective
measurement) (see Statistical methodology column), maternal smoking,
breastfeeding, current wheeze, early life paracetamol use, gross national
income (tested for interaction only)
Trasande et al. [26] 11 532 Any antibiotic at
⩽24 months
Adjusted difference (β) in zBMI at 38
months and 7 years
British 1990 growth reference Birth weight, maternal parity, maternal race, maternal social class,
maternal education, parental BMI (pre-pregnancy and later), first
trimester smoking, breastfeeding, timing of introduction of
complementary foods, time per day watching television, in car on
weekdays and weekends, dietary patterns at 38 months, sleep duration
at 7 years
aOR for overweight at 38 months
and 7 years
Ajslev et al. [22] 28 354 Any antibiotic at
<6 monthsa
aOR for overweight at 7 years International Obesity Task
Force reference (2007, 2012)
Maternal age, socioeconomic status, pre-pregnancy BMI, gestational
weight gain, smoking, paternal BMI, parity, birth weight, sex, exclusive
breastfeeding and age at 7 year follow-up
Bailey et al. [30] 64 580 Any antibiotic at
⩽23 months
Adjusted hazard ratio for obesity
at 24–59 months
Centers for Disease Control
and Prevention 2000
reference
Race/ethnicity, age at first primary care visit and number of primary care
visits, sex, practice location at first visit, insurance coverage, common
childhood infection diagnoses in first 2 years, calendar year and practice
of first entry to primary care system, oral steroids and anti-reflux
medication
Azad et al. [23] 616 Any antibiotic at
<12 months
aOR for overweight at 9 years Centers for Disease Control
and Prevention 2000
reference
Sex, birth weight, breastfeeding, maternal overweight, smoke exposure
at birth, family income, sibship, diet, physical activity, current asthma,
maternal asthma
aOR for overweight at 12 years
Rogawski et al. [27] 497 Any antibiotic at
<6 months
Adjusted difference (β) in
weight-for-length z-score at
6 months to 3 years
World Health Organization
2006 standards
Sex, prior growth z-score (measured at the beginning of the month),
socioeconomic status, maternal education, household hygiene,
household crowding, low birth weight, preterm birth, caesarean
delivery, exclusive breastfeeding, number of days with infection/severe
illness, number of days with diarrhoea, number of severe diarrhoea
events, dehydration during diarrhoea, oral rehydration, hospitalisation
events, days with diarrhoea in the previous month
Schwartz et al. [25] 1 63 820 Any (and cumulative)
antibiotic at ⩽18 years
Adjusted difference (β) in BMI at
⩽18 years
Age, sex, race/ethnicity, medical assistance
Gerber et al. [29] 38 522 Any antibiotic at
<6 months
Adjusted difference in rate of
weight gain (%) between 2 and
5 years
Singleton analysis: adjustments made for both mean-level covariates
(sex, birth weight, race, Medicaid insurance status, number of siblings,
birth year, baseline length, primary care site) and rate-level covariates
(as above, excluding primary care site)
Twin analysis: sex, birth weight, baseline length
Li et al. [32] 2 60 556 Any antibiotic at
<12 months among
children with infection
aOR for obesity at 2–18 years Centers for Disease Control
and Prevention 2000
reference
Infection type and number of episodes (diagnoses >2 weeks apart),
maternal age and race/ethnicity, pre-pregnancy BMI, preterm delivery,
sex, low birth weight, maternal antibiotic use and infections during
pregnancy, maternal education, marital status, smoking during
pregnancy, mode of delivery, timing of initial prenatal care, gestational
or pre-existing diabetes, breastfeeding
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an important limitation of other studies [21–26, 29, 31, 33]
(online Supplementary Tables S4 and S5).
Quantification of weight gain
Four studies examining measures of relative BMI or weight as out-
comes (Table 1) quantified the absolute magnitude of weight gain
associated with antibiotic exposure [25–27, 29]. Estimates ranged
from increases of 0.001 and 0.032 kg at 2 years of age among boys
and girls exposed to antibiotics in the first 6 months of life [27] to
a maximum weight gain of 1.50 kg by 15 years of age associated
with exposure to macrolides [25]. One study estimated 0.09 kg
increased weight among 38 month old children exposed to anti-
biotics up to 2 years of age [26], whilst another estimated a
0.15 kg increase between 2 and 5 years of age attributable to anti-
biotic use in the first 6 months of life [29]. In all cases, reported
gains in weight approximated to <2.9% of the age-specific popu-
lation median, proportions that would be unlikely to notably alter
risk of adverse outcomes (online Supplementary Table S6).
Discussion
Clarifying the existence and nature of associations between anti-
biotic use in early life and subsequent risk of child obesity is
essential to guide appropriate policies and strategies relating to
child health and to use of antibiotic medications. We examined
observational studies exploring the relation between early child-
hood antibiotic use and measures of child body mass. The totality
of evidence was inconsistent, with key differences in study design
potentially contributing to varying conclusions. Overall, there was
no strong evidence supporting clinically relevant associations
between antibiotic exposure and body mass in childhood.
Further comprehensive and comparable studies using routine
clinical data may help clarify this association.
Although the exact measures varied by study, associations
reported between antibiotic use and child body mass were gener-
ally not appreciable in terms of effect size and statistical strength.
In certain studies, associations were only apparent when examin-
ing exposure to four or more antibiotic courses [21, 30]. Trends or
patterns, such as those relating to consecutive exposure windows
or antibiotic class, were often inconsistent across studies or study
subgroups [21, 23, 28–33]. Notably, studies quantifying observed
associations did not indicate important absolute gains in weight
related to antibiotic exposure, suggesting that if this association
does exist, it is not likely to be clinically relevant [25–27, 29].
Findings reported in studies must also be considered within
the context of their specific limitations. These limitations ranged
from small population or subgroup sample sizes [23, 27, 31] to
errors in ascertainment of antibiotic exposure measured through
parental recall [22, 24, 26, 27] or by prescriptions [23, 25, 27, 29,
30] or examination of only specific kinds of antibiotics [22], and
the inability to measure adherence to treatment. Such errors in
ascertainment of antibiotic exposure may limit the ability of stud-
ies to detect associations. Not all studies controlled for a compre-
hensive range of relevant confounders, and most importantly,
most studies did not sufficiently examine confounding by clinical
indication [21–31, 33, 46]. We found only one study to have
accounted for this, which reported no association between anti-
biotic use and obesity risk among children with infection, and
demonstrated the potential for observing erroneous positive asso-
ciations when including uninfected children in the reference
group [32]. These findings indicate that associations reported inTa
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other studies must be cautiously interpreted, and highlight the
need for further, more robust evidence [21–31, 33].
In this review, we were unable to synthesise effect estimates
meaningfully given the high degree of heterogeneity among stud-
ies, which included differences in study populations and settings,
observation windows, definitions of exposures and outcomes,
inclusion of potential confounders and effect modifiers and
choice of analytic approaches. To improve comparability and
enable synthesis of data in meta-analyses, future studies should
ideally: (i) define all exposures and outcomes, including their
respective time windows, consistently with previous studies, (ii)
consider using multiple analytic methods as employed in previous
research and (iii) control for all confounding factors included in
previous studies, including accounting for confounding by indica-
tion. As stronger evidence emerges regarding the characterisation
and contribution of related measures in childhood, such as waist
circumference, to future disease risk, studies may also consider
such measures as potentially important outcomes [23, 47].
Given the effect sizes observed here, future studies must be
based on large populations in order to allow for more precise esti-
mation of association. Given this required scale and complexity,
such analyses would be best facilitated by the use of routine clin-
ical data captured in electronic health records, as demonstrated in
key studies reviewed here [21, 23, 25, 29, 30, 32]. Electronic health
records provide a platform for obtaining large-scale, longitudinal
patient data, as well as facilitating the collection of information on
infection type, test results, treatment dose, duration and response
and other potential confounding factors. They may additionally
be utilised to prospectively recruit patients into future, large
scale studies.
The evidence reviewed here is insufficient to justify the risk of
child obesity as an important reason to limit antibiotic use.
Table 2. Overall associations reported between any antibiotic exposure in early life and measures of child body mass
Study Exposure definition and age window Outcome and age of measurement
Overall association
estimate (95% CI)
Ajslev et al. [22] Any antibiotic at <6 months aOR for overweight at 7 years 1.04 (0.79–1.37)
Azad et al. [23] Any antibiotic at <12 months aOR for overweight at 9 years 1.74 (1.04–2.94)*
aOR for overweight at 12 years 2.56 (1.36–4.79)*
Rogawski et al. [27] Any antibiotic at <6 months Adjusted difference (β) in weight-for-
length z-score at 6 months to 3 years
−0.10 (−0.23 to 0.02)
Gerber et al. [29] Any antibiotic at <6 months Adjusted difference in rate of weight
gain (%) between 2 and 5 years
0.7 (−0.1 to 1.5)
Li et al. [32] Any antibiotic at <12 months among children with infection aOR for obesity at 2–18 years 1.01 (0.98–1.04)
Rogawski et al. [28] 7-day increase in antibiotic exposure duration at <6 months Adjusted difference (β) in WAZ at
6 months to 2 years
0.03 (0.00–0.05)
zBMI, body mass index-for-age z-score; WAZ, weight-for-age z-score; aOR, adjusted odds ratio.
*p < 0.05.
See Table 1 and online Supplementary Table S3 for adjustments relating to analyses in each study.
Measures of association are relative to unexposed group unless stated otherwise. Blank cells indicate that no overall association estimate was reported.
Table 3. Sex-specific associations reported between any antibiotic exposure in early life and measures of child body mass
Study Exposure definition Outcome measure
Association estimate
(95% CI or p value)
Saari et al.[33] Any antibiotic at <24 months Adjusted difference (β) in zBMI at ⩾24 months Boys: 0.13 (0.07–0.19)*
Girls: 0.07 (0.01–0.13)*
Murphy et al. [24] Any antibiotic at <12 months Adjusted difference (β) in BMI at 5–8 years Boys: 0.107 ( p < 0.001)a*
Girls: −0.008 ( p = 0.75)ab
Azad et al. [23] Any antibiotic at <12 months aOR for overweight at 9 years Boys: 2.19 (1.06–4.54)*
Girls: 1.20 (0.53–2.70)
aOR for overweight at 12 years Boys: 5.35 (1.94–14.72)*
Girls: 1.13 (0.46–2.81)c
Rogawski et al. [27] Any antibiotic at <6 months Adjusted difference (β) in weight-for-length
z-score at 6 months to 3 years
Boys: −0.15 (−0.32 to 0.02)
Girls: −0.06 (−0.22 to 0.10)
Measures of association are relative to unexposed group unless stated otherwise.
zBMI, body mass index-for-age z-score; aOR, adjusted odds ratio.
*p < 0.05.
See Table 1 and online Supplementary Table S3 for adjustments relating to analyses in each study.
aTwo-tailed p values reported, as 95% CIs were not provided.
bp for interaction = 0.002.
cp for interaction = 0.05.
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However, multiple other reasons exist for improving monitoring
and management of antibiotic use, including the development
of antibiotic resistance. The importance of antibiotic stewardship
programmes to achieve appropriate use of antibiotics is increas-
ingly being recognised, with recent evidence suggesting notable
effects of such initiatives on overall antibiotic use, infection inci-
dence and other patient outcomes in hospitals [48–50]. The
expansion of these programmes may help address antibiotic
resistance on a wider scale, and thus contribute to reducing asso-
ciated morbidity and mortality [51]. However, the evidence here
does not support a tangible effect of such programmes on the cur-
rent burden of child obesity, and suggests that resources aimed
towards child obesity prevention would be better placed in
existing strategies and initiatives targeting appropriate nutrition
and physical activity in early life and later childhood [52].
We followed a systematic literature search and selection
method to identify all relevant studies investigating the relation
between early life antibiotic use and child obesity, and present
here a detailed qualitative synthesis of identified studies.
However, certain limitations must be considered. We included
only English language publications in our search, and are unable
to rule out publication bias, although the presence of such bias
would support our interpretation of the current evidence. The
inability to quantitatively synthesise effect estimates limits our
ability to present more definitive conclusions, and points towards
the need for more harmonised methods to assess this association.
Finally, this review examined only exposure to antibiotics for
medical use, and did not capture potential exposure through
other methods, such as low-dose antibiotics present in food.
Although this has been recognised as a potentially important
source of exposure [11, 53], few studies, to our knowledge, have
quantified it and explored its association with outcomes in
humans, and it remains a potentially important area for future
research.
In this review, we observed no robust evidence implicating
antibiotic use as an important risk factor for child obesity, with
notable heterogeneity among studies limiting more conclusive
interpretations. Further more detailed, comparable studies are
required to clearly determine the existence of such associations.
Regardless, there is a well-justified need to achieve more appropri-
ate use of antibiotics [51]. Furthermore, multiple comprehensively
researched risk factors may be targeted to address child obesity
[52]. Efforts in these directions will be key for addressing both
these concerning public-health issues on a large scale.
Fig. 2. Association between antibiotic exposure in specific age windows and mea-
sures of child body mass: selected risk measures reported in reviewed studies.
aOR, adjusted odds ratio; aHR, adjusted hazard ratio. 1Estimates displayed for chil-
dren exposed to two or more courses of antibiotics. See online Supplementary
Table S3 for adjustments relating to analyses in each study, and online
Supplementary Table S4 for additional estimates reported from other studies.
Fig. 3. Association between antibiotic course number and measures of child body
mass: selected risk measures reported in reviewed studies. aOR, adjusted odds
ratio; aHR, adjusted hazard ratio. See online Supplementary Table S3 for adjustments
relating to analyses in each study, and online Supplementary Table S5 for additional
estimates reported from other studies.
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Table 4. Association between antibiotic class and measures of child body mass
Study group Summary measure and outcome Antibiotic class Association estimate (95% CI)
Studies stratifying by exposure window (months)
<6 months 6–11 months 12–17 months 18–23 months
Saari et al. [33] aOR for overweight at ⩾24 months Penicillins – boys 1.28 (0.99–1.62) 1.29 (1.04–1.49)* 1.28 (0.95–1.42) 0.95 (0.78–1.28)
Cephalosporins – boys 1.44 (0.97–2.35) 1.44 (1.04–1.84)* 1.46 (1.06–1.82)* 1.10 (0.78–1.43)
Macrolides – boys 1.65 (1.09–2.31)* 1.41 (1.09–1.70)* 1.10 (0.84–1.34) 1.42 (1.18–1.93)*
Penicillins – girls 1.20 (0.87–1.66) 1.20 (0.97–1.50) 1.04 (0.81–1.33) 1.15 (0.87–1.52)
Cephalosporins – girls 1.25 (0.67–2.35) 1.18 (0.79–1.76) 1.27 (0.88–1.82) 1.11 (0.75–1.64)
Macrolides – girls 1.53 (0.90–2.60) 1.11 (0.82–1.50) 1.28 (0.95–1.71) 1.21 (0.88–1.65)
<6 months 6–11 months 12–17 months 18–23 months
Baileya et al. [30] Adjusted hazard ratio for obesity at
24–59 months
Broad spectrumb
Narrow spectrumb
1.12 (1.03–1.19)*
1.03 (0.6–1.08)
1.1 (1.05–1.15)*
0.8 (0.3–1.04)
1.06 (0.99–1.12)
1.01 (0.6–1.06)
1.05 (0.7–1.15)
1.02 (0.4–1.11)
<6 months <24 months
Gerber et al. [29] Adjusted difference in rate of weight
gain (%) between 2 and 5 years
Broad spectrum (nonmacrolide)
Broad spectrum (macrolide)
Narrow spectrum
−0.3 (−2.1 to 1.5)
2.2 (−1.2 to 5.7)
0.4 (−0.6 to 1.3)
2.2 (0.7–3.8)*
2.4 (0.6–4.2)*
1.9 (0.5–3.2)*
⩽12 months
Li et al. [32] aOR for obesity at 2–18 years Broad spectrum
Narrow spectrum
1.02 (0.99–1.05)
1.01 (0.97–1.04)
Studies stratifying by number of antibiotic courses
1–2 courses 3–5 courses 5+ courses
Scott et al. [21] aOR for obesity at 4 years Anaerobic coveragec
No anaerobic coveragec
1.09 (0.95–1.25)
1.09 (0.93–1.27)
1.45 (0.91–1.68)
1.24 (0.91–1.68)
1.46 (1.09–1.96)*
1.00 (0.63–1.60)
1 course 2+ courses
Mbakwa et al. [31] Adjusted difference (β) in zBMI at
⩽10 years
aOR for overweight at ⩽10 years
Broad spectrum β-lactams
Narrow spectrum β-lactams
Macrolide
Antimetabolite
Others
Broad spectrum β-lactams
Narrow spectrum β-lactams
Macrolide
Antimetabolite
Others
−0.05 (−0.16 to 0.06)
0.08 (−0.10 to 0.26)
0.09 (−0.05 to 0.23)
−0.05 (−0.30 to 0.19)
0.13 (−0.29 to 0.56)
0.95 (0.68–1.34)
1.00 (0.57–1.76)
1.29 (0.89–1.86)
0.83 (0.33–2.11)
1.62 (0.52–5.06)
0.07 (−0.04 to 0.19)
0.16 (−0.18 to 0.49)
−0.07 (−0.28 to 0.14)
−0.02 (−0.41 to 0.37)
−0.16 (−0.51 to 0.19)
1.20 (0.86–1.67)
0.41 (0.06–2.63)
0.64 (0.35–1.16)
0.67 (0.19–2.31)
0.50 (0.21–1.20)
1 or 1+ courses 2+ courses
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